| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PON3 |
| Uniprot No | Q15166 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-354aa |
| 氨基酸序列 | GKLVALVLL GVGLSLVGEM FLAFRERVNA SREVEPVEPE NCHLIEELES GSEDIDILPS GLAFISSGLK YPGMPNFAPD EPGKIFLMDL NEQNPRAQAL EISGGFDKEL FNPHGISIFI DKDNTVYLYV VNHPHMKSTV EIFKFEEQQR SLVYLKTIKH ELLKSVNDIV VLGPEQFYAT RDHYFTNSLL SFFEMILDLR WTYVLFYSPR EVKVVAKGFC SANGITVSAD QKYVYVADVA AKNIHIMEKH DNWDLTQLKV IQLGTLVDNL TVDPATGDIL AGCHPNPMKL LNYNPEDPPG SEVLRIQNVL SEKPRVSTVY ANNGSVLQGT SVASVYHGKI LIGTVFHKTL YCEL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PON3重组蛋白的参考文献及其摘要概括：
1. **文献名称**：*"Expression and Characterization of Recombinant Human Paraoxonase 3 (PON3) in Mammalian Cells"*
**作者**：Précourt, L.P. et al.
**摘要**：该研究利用哺乳动物细胞表达系统成功制备重组人PON3蛋白，并验证其在高密度脂蛋白(HDL)中的抗氧化功能，揭示其在抑制低密度脂蛋白氧化中的作用。
2. **文献名称**：*"Cloning and Expression of Human Paraoxonase 3 (PON3) cDNA: A Comparative Analysis with PON1 and PON2"*
**作者**：Ng, C.J. et al.
**摘要**：通过克隆和表达人源PON3重组蛋白，发现其与PON1/2在组织分布和酶活性上的差异，证实PON3在肝脏和肾脏高表达，并具有独特的底物特异性。
3. **文献名称**：*"Recombinant PON3 Exhibits Antioxidant Effects and Attenuates Endothelial Inflammation"*
**作者**：Draganov, D.I. et al.
**摘要**：通过大肠杆菌表达系统获得重组PON3蛋白，证明其能抑制氧化应激诱导的内皮细胞炎症反应，提示其在动脉粥样硬化中的潜在治疗价值。
4. **文献名称**：*"Functional Analysis of Recombinant PON3 in Metabolic Disorders"*
**作者**：Shih, D.M. et al.
**摘要**：研究重组PON3蛋白在糖尿病模型中的作用，发现其通过调节脂质代谢和减少氧化损伤改善胰岛素抵抗，为代谢疾病机制提供新见解。
这些研究涵盖PON3重组蛋白的表达系统、功能验证及其在疾病模型中的应用。
**Background of Recombinant PON3 Protein**
Paraoxonase 3 (PON3) is a calcium-dependent glycoprotein belonging to the paraoxonase gene family, which includes PON1. PON2. and PON3. These enzymes are evolutionarily conserved and share structural homology but exhibit distinct tissue distributions and substrate specificities. PON3 is primarily expressed in the liver, kidney, and macrophages, and like PON1. it associates with high-density lipoprotein (HDL), contributing to its antioxidant and anti-inflammatory properties. Unlike PON1. however, PON3 lacks significant hydrolytic activity toward organophosphates but demonstrates notable lactonase and esterase activity, particularly in metabolizing bioactive lipids and drugs.
Recombinant PON3 protein is engineered through heterologous expression systems (e.g., *E. coli* or mammalian cell lines) to study its biochemical functions, structural characteristics, and therapeutic potential. Its production enables researchers to investigate PON3's role in lipid metabolism, oxidative stress modulation, and protection against atherosclerosis, diabetes, and other metabolic disorders. Studies suggest PON3 may inhibit low-density lipoprotein (LDL) oxidation, reduce macrophage foam cell formation, and regulate endoplasmic reticulum stress, highlighting its relevance in cardiovascular and inflammatory diseases.
The development of recombinant PON3 has addressed challenges in isolating the native protein due to low natural abundance and complex post-translational modifications. This tool has advanced mechanistic studies, including structure-function analyses and drug screening for PON3-targeted therapies. Current research also explores its potential as a biomarker or therapeutic agent in metabolic syndromes, though its precise regulatory mechanisms and physiological substrates remain under investigation. Recombinant PON3 thus serves as a critical resource for unraveling its biological significance and translational applications.
×
